Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2

Conditions

Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Glioma 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Temozolomide 31Radiotherapy 25Magnetic Resonance Spectroscopy 17Radiation 13Surgical Procedures, Operative 12Specimen Handling 9Radiotherapy, Conformal 9Bevacizumab 9Immunoglobulin G 8Disulfides 8Carmustine 8Vorinostat 7Radiotherapy, Intensity-Modulated 7Erlotinib Hydrochloride 7Chemotherapy, Adjuvant 7temsirolimus 6cediranib 6Sirolimus 6motexafin gadolinium 5Sorafenib 5Nivolumab 5Cilengitide 5Carboplatin 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5tipifarnib 4Lapatinib 4Congresses as Topic 4veliparib 3Procarbazine 3O(6)-benzylguanine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Glioblastoma × tandutinib × Clear all
NCT00379080 2017-04-07

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
60 enrolled 22 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡